{"id":"at-001","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Transient liver enzyme elevation"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AT-001 works by binding to messenger RNA encoding apolipoprotein(a) in the liver, leading to degradation of that mRNA and reduced synthesis of lipoprotein(a), a genetically determined risk factor for cardiovascular disease. By lowering circulating lipoprotein(a) levels, the drug aims to reduce atherosclerotic cardiovascular disease risk in patients with elevated baseline levels.","oneSentence":"AT-001 is an antisense oligonucleotide that reduces production of lipoprotein(a) by targeting hepatic apolipoprotein(a) synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:51.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Elevated lipoprotein(a) for reduction of cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT05041101","phase":"PHASE1, PHASE2","title":"Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-21","conditions":"Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma","enrollment":6},{"nctId":"NCT04083339","phase":"PHASE3","title":"Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Applied Therapeutics, Inc.","startDate":"2019-09-20","conditions":"Diabetic Cardiomyopathies","enrollment":675},{"nctId":"NCT04365699","phase":"PHASE2","title":"Cardiovascular Effects of COVID-19","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-04-08","conditions":"COVID-19","enrollment":81},{"nctId":"NCT03062384","phase":"NA","title":"AT-001 for Long-term Preservation of Brain Health in Aging","status":"COMPLETED","sponsor":"University of Kentucky","startDate":"2016-05","conditions":"Oxidative Stress","enrollment":95},{"nctId":"NCT01731093","phase":"PHASE1","title":"Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress","status":"COMPLETED","sponsor":"Alltech Life Sciences Inc.","startDate":"2012-03","conditions":"Oxidative Stress","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AT-001","genericName":"AT-001","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AT-001 is an antisense oligonucleotide that reduces production of lipoprotein(a) by targeting hepatic apolipoprotein(a) synthesis. Used for Elevated lipoprotein(a) for reduction of cardiovascular risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}